Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib in Newly-Diagnosed and Recurrent Glioblastoma
NCT04614909Phase 1Completed
- Sponsor
- Ivy Brain Tumor Center
- Start
- Jan 2021
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pamiparib in glioblastoma (GBM) (3 arms), sponsored by Ivy Brain Tumor Center. Primary endpoint: Systemic plasma PK profile parameters at Day 4. Started Jan 2021; status: completed.
02
Drugs
pamiparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04614909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614909.